Vycor Medical GAAP EPS of $0.00, revenue of $0.41M
Vycor Medical reported Q3 GAAP EPS of $0.00 and revenue of $0.41M, down 19.6% year-over-year, according to the company's press release.
How this was made
The 30-second read
Why it matters
The earnings miss is likely to trigger short‑term selling pressure on VYCO.
Market read
Micro‑cap earnings release with weak numbers; limited broader market relevance.
What to watch
Potential upcoming regulatory approvals or partnership announcements could offset the weak quarter.
Background
Vycor Medical (VYCO) released its Q3 2026 GAAP earnings, reporting zero EPS and a modest revenue decline.
Ticker impact
Q3 GAAP EPS of $0.00 and revenue of $0.41M, down 19.6% YoY.
likely downward pressure as market prices in weak results
Micro‑cap earnings with no profit and revenue contraction typically trigger sell‑offs.
Market effects
Minimal impact on broader biotech sector due to small size.
Negligible effect on US markets overall.
Limited to investors tracking micro‑cap biotech stocks.
Counterpoint
If the company has pipeline catalysts not reflected in Q3, the drop may be overblown.
Key entities
- CompanyVycor Medical, Inc.
US‑listed biotech firm reporting Q3 results.

